Abstract
Wagenlehner and colleagues1 demonstrated non-inferiority and superiority with respect to a primary endpoint of composite success (microbiological plus clinical) of cefepime/taniborbactam vs. meropenem in treating complicated urinary tract infections and acute pyelonephritis caused by carbapenem-susceptible gram-negative bacteria in adults. A major area of interest in real-world application of cefepime/taniborbactam is its potential role in treating carbapenem-resistant infections, which deserves further investigation.
Copyright © 2024. Published by Elsevier Inc.
MeSH terms
-
Anti-Bacterial Agents* / pharmacology
-
Anti-Bacterial Agents* / therapeutic use
-
Borinic Acids
-
Carbapenems* / pharmacology
-
Carbapenems* / therapeutic use
-
Carboxylic Acids
-
Cefepime* / pharmacology
-
Cefepime* / therapeutic use
-
Cephalosporins / pharmacology
-
Cephalosporins / therapeutic use
-
Drug Combinations
-
Gram-Negative Bacterial Infections / drug therapy
-
Humans
-
Meropenem / pharmacology
-
Meropenem / therapeutic use
-
Pyelonephritis / drug therapy
-
Pyelonephritis / microbiology
-
Urinary Tract Infections* / drug therapy
-
Urinary Tract Infections* / microbiology
Substances
-
Cefepime
-
Anti-Bacterial Agents
-
Carbapenems
-
taniborbactam
-
Cephalosporins
-
Drug Combinations
-
Meropenem
-
Borinic Acids
-
Carboxylic Acids